-
Mashup Score: 26The Mass General Brigham Heart Failure & Shock Course - 2 day(s) ago
This Comprehensive Mass General Brigham Heart Failure & Shock symposium will provide practical insights for all clinicians who manage patients with heart failure (HF) and cardiogenic shock. This offering is a 2-part course, of which participants can choose to partake in one or both parts. The first half of the course will be an in-depth review of cardiogenic shock while the second half of the course focuses on HF guideline directed medical therapy (GDMT) and beyond – the latest HF innovations with an emphasis on device- and technology-based therapies. Massachusetts General Hospital Faculty and guest speakers who are leaders in the field will address state-of-the-art issues including: up-to-date knowledge of cardiogenic shock pathophysiology, shock phenotypes and trajectories; best practices in shock diagnosis and management; the roles of temporary mechanical circulatory support in shock treatment; emerging heart failure therapies; nuts and bolts of day to day HF management by our APPs
Source: cmecatalog.hms.harvard.eduCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 24The Mass General Brigham Heart Failure & Shock Course - 23 day(s) ago
This Comprehensive Mass General Brigham Heart Failure & Shock symposium will provide practical insights for all clinicians who manage patients with heart failure (HF) and cardiogenic shock. This offering is a 2-part course, of which participants can choose to partake in one or both parts. The first half of the course will be an in-depth review of cardiogenic shock while the second half of the course focuses on HF guideline directed medical therapy (GDMT) and beyond – the latest HF innovations with an emphasis on device- and technology-based therapies. Massachusetts General Hospital Faculty and guest speakers who are leaders in the field will address state-of-the-art issues including: up-to-date knowledge of cardiogenic shock pathophysiology, shock phenotypes and trajectories; best practices in shock diagnosis and management; the roles of temporary mechanical circulatory support in shock treatment; emerging heart failure therapies; nuts and bolts of day to day HF management by our APPs
Source: cmecatalog.hms.harvard.eduCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 165
This randomized clinical trial examines the safety of the exclusion of aspirin as part of an antithrombotic regimen including a vitamin K antagonist with a fully magnetically levitated left ventricular assist device.
Source: jamanetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 165
This randomized clinical trial examines the safety of the exclusion of aspirin as part of an antithrombotic regimen including a vitamin K antagonist with a fully magnetically levitated left ventricular assist device.
Source: jamanetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 165
This randomized clinical trial examines the safety of the exclusion of aspirin as part of an antithrombotic regimen including a vitamin K antagonist with a fully magnetically levitated left ventricular assist device.
Source: jamanetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 165
This randomized clinical trial examines the safety of the exclusion of aspirin as part of an antithrombotic regimen including a vitamin K antagonist with a fully magnetically levitated left ventricular assist device.
Source: jamanetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 159
This randomized clinical trial examines the safety of the exclusion of aspirin as part of an antithrombotic regimen including a vitamin K antagonist with a fully magnetically levitated left ventricular assist device.
Source: jamanetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 159
This randomized clinical trial examines the safety of the exclusion of aspirin as part of an antithrombotic regimen including a vitamin K antagonist with a fully magnetically levitated left ventricular assist device.
Source: jamanetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 159
This randomized clinical trial examines the safety of the exclusion of aspirin as part of an antithrombotic regimen including a vitamin K antagonist with a fully magnetically levitated left ventricular assist device.
Source: jamanetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 3JHLT: The Podcast: Episode 35: October 2023 - 6 month(s) ago
The JHLT Digital Media Editors explore two manuscripts from the October issue of The Journal of Heart and Lung Transplantation—the first on lung transplantation in patients with stacked risks, and the second on bacterial pathogens found at driveline exit sites in patients with ventricular assist devices. Digital Media Editor Marty Tam, MD, assistant professor in the division of cardiovascular medicine at the University of Michigan, hosts this episode. First, hear from senior author Edward Cantu, MD, MSCE, on his team’s study “.” Lung transplant centers are increasingly evaluating patients with multiple risk factors for adverse post-transplant outcomes, yet there is little data of the effects of these risks as they stack. The authors of the study used the UNOS registry data linked to the National Inpatient Sample (NIS) to create a national encounter-level sample of healthcare data in the United States, then applied a probabilistic matching algorithm using 7 variables and determined
Source: thejhlt.libsyn.comCategories: General Medicine News, CardiologistsTweet
As you said 👋 to #ISHLT2024, check out 👇 our 1st #MGB Heart Failure & Shock course 9/12-14/24 in Boston, MA. Loved talks on #cardiogenicshock? More on the PACCS trial? Come to Boston! https://t.co/80RiiKK4lg @ISHLT @harvardmed @MGHHeartHealth